NGN-401 Clinical Development and Trial Design - NGN-401 is being developed as a potential one-time, best-in-class gene therapy for Rett syndrome, showing durable multidomain improvements across the disease spectrum[8] - The Embolden registrational trial, aligned with the FDA, is a single trial for ages ≥ 3 years, with multiple participants dosed in 4Q'25[8] - The Embolden trial is a single-arm, baseline-controlled, open-label trial of NGN-401 in females with Rett Syndrome, using a one-time 1E15 vg dose in patients ≥ 3 years[30, 31] - The primary endpoint for the Embolden trial at 12 months is a responder-based composite endpoint, requiring a 35% response rate (7 of 20 participants) for success[32] Market Opportunity and Commercial Readiness - Rett syndrome presents a multi-billion-dollar market opportunity for disease-modifying gene therapy, with an estimated prevalence of ~15,000 – 20,000 patients in major markets (US, EU, and UK)[9, 13] - Payors are receptive to reimbursement for Rett syndrome treatments, valuing functional changes that are clinically meaningful and show improvements in activities of daily living[13] - Early commercial-readiness activities are underway, including positioning Embolden clinical trial sites for rapid conversion to commercial sites at launch[9, 42] Phase 1/2 Clinical Trial Data - Interim Phase 1/2 data showed 100% of participants demonstrated functional improvements across core disease domains (fine motor/hand function, gross motor/ambulation, and communication)[24] - A total of 35 developmental milestones were gained in the Phase 1/2 trial, with no plateau observed out to 24 months[24] - In the Phase 1/2 trial, 88% of participants achieved an improved CGI-I score[24] Upcoming Milestones and Financial Position - Complete dosing of the Embolden trial is expected in 2Q'26, with presentation of 12+ months Phase 1/2 data for all 10 participants planned for mid-2026[10] - The company has a strong cash balance expected to fund operations through Embolden data readout, BLA submission, and key pre-launch activities (as of 1Q'28)[49]

The New Backbone of Retina Care: Moving Beyond Lifelong Injections Corporate Overview J.P. Morgan Healthcare Conference | January 2026 This Presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities. © 2026 4D Molecular Therapeutics. All Rights Reserved. 2 Overview 1 4DMT Vision & Pipeline 2 4D-150 Overview & 2025 Accomplishments 3 Retinal Vascular Disease Market & Unmet Medical Needs 4 Derisking Phase 3 & Commercialization 5 2026-27 Catalysts 6 Summary © 2026 4D Mo ...

Turning Strategy into Results Jean-Christophe Tellier, CEO 44th Annual J.P. Morgan Healthcare Conference January 14th, 2026 Disclaimer & Safe Harbor This document contains forward-looking statements, including, without limitation, statements containing the words "potential", "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All sta ...

Financial Performance - Net income for 4Q25 was $5.4 billion, or $1.62 per diluted share, including $612 million in severance expense[5] - Excluding severance expense, net income was $5.8 billion, or $1.76 per diluted share[7] - Revenue reached $21.3 billion, a 4% increase[7] - Noninterest income was $9.0 billion, up 5%[4] - Noninterest expense was $13.7 billion, down 1%[4] - Pre-tax pre-provision profit was $7.6 billion, up 17%[4] Balance Sheet and Capital - Average loans totaled $955.8 billion, up 5%[4] - Average deposits reached $1.4 trillion, up 2%[4] - Common Equity Tier 1 (CET1) capital was $137.3 billion[4] - CET1 ratio stood at 10.6%[4] - Liquidity coverage ratio (LCR) was 119%[4] - Total Loss Absorbing Capacity (TLAC) ratio was 23.2%[4]

January 14, 2026 Scorpio Tankers Inc. Capital Link Presentation Disclaimer and Forward-looking Statements This presentation includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect Scorpio Tankers Inc.'s ("Scorpio's") current views with respect to future events and financial performance. The words "believe," "anticipate," "intend," "estimate," "forecast," "project," " ...

Financial Performance - United Community Banks reported GAAP diluted earnings per share of $0.70 for 4Q25 and $2.62 for the full year[12, 19] - The operating diluted earnings per share were $0.71 for 4Q25 and $2.71 for the full year[12, 19] - The company's GAAP return on assets was 1.21% for 4Q25 and 1.17% for the full year[12, 19] - The operating return on assets was 1.22% for 4Q25 and 1.20% for the full year[14, 19] - Net interest margin was 3.62% for 4Q25, an increase of 36 bps year-over-year[12] Balance Sheet and Loan Portfolio - Total assets reached $28 billion[9] - Total deposits amounted to $23.8 billion[9] - Total loans reached $19.4 billion[9] - The loan portfolio grew by $209 million, or 4.4% annualized, from 3Q25[38] - Loans grew $1.2 billion or 6.6% from 4Q24[38]

Company Overview - Crane NXT is a premier industrial technology company with approximately $1.6 billion in 2025 sales[9] - The company has approximately 50% recurring and reoccurring revenue[10] - The adjusted segment operating margin is approximately 25%[11] - Net leverage is approximately 2.3x[12] Business Segments - Crane Payment Innovations (CPI) has approximately $850 million in 2025 sales[18] - Security & Authentication Technologies has approximately $785 million in 2025 sales, including 8 months of De La Rue Authentication[18, 20] Customer Base - Approximately 65% of customers have been with the business for more than 20 years[16] - Sales by geography: Americas ~50%, APAC ~15%, Europe ~15%, MEA ~10%, SAT ~10%[15] Acquisition - Antares Vision has approximately €200 million in 2024 revenue and approximately 15% adjusted EBITDA margin[22]

Bank of America 4Q25 Financial Results January 14, 2026 Note: IB stands for investment banking. ROA stands for return on average assets. ROE stands for return on average common shareholders' equity. ROTCE stands for return on average tangible common shareholders' equity. 5 End of period (EOP). 6 CET1 stands for common equity tier 1 capital. CET1 ratio at December 31, 2025, is preliminary. 7 GLS stands for average Global Liquidity Sources. See note A on slide 27 for definition of Global Liquidity Sources. 8 ...

Oncolytics Biotech PELAREOREP a transformative dsRNA immunotherapy platform for gastrointestinal tumors January 2026 Forward-Looking Statements Oncolytics Biotech Confidential This presentation is strictly confidential. Neither the Securities and Exchange Commission nor any state or foreign securities commission or regulatory authority has passed upon the adequacy or accuracy of this presentation. Any representation to the contrary is a criminal offense. This presentation does not constitute an offer to sel ...

America's Cross-Domain Force Multiplier NASDAQ: PDYN / January 2026 Disclaimer This presentation and any related oral statements contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, but not limited to, statements regarding Palladyne AI's preliminary unaudited revenue for the year ended December 31, 2025, preliminary unaudited backlog and cash and cash equivalents as of December 31, 2025, estimated cash burn for 2026, anticipated growth and ...